Vivo Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Vivo Capital’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,841	Closed	-$121K	–	49
2019 Q1	$121K	Sell	2,841 -2,744	-49%	-$62.2K	0.01%	48
2018 Q4	$81K	Hold	5,585	–	–	0.01%	44
2018 Q3	$391K	Hold	5,585	–	–	0.04%	42
2018 Q2	$414K	Hold	5,585	–	–	0.05%	39
2018 Q1	$532K	Sell	5,585 -8,701	-61%	-$1.49M	0.08%	33
2017 Q4	$1.84M	Hold	14,286	–	–	0.4%	27
2017 Q3	$970K	Hold	14,286	–	–	0.2%	28
2017 Q2	$1.35M	Hold	14,286	–	–	0.34%	25
2017 Q1	$2.05M	Hold	14,286	–	–	0.6%	21
2016 Q4	$1.81M	Buy	+14,286	New	+$1.99M	0.6%	20

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital's VIRX Position: Q2 2019 in Review

Vivo Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2019, closing a stake of 2,841 shares — an estimated $121K sold.

Vivo Capital first reported a position in VIRX in Q4 2016 and held it in 10 quarters. The position peaked at $2.05M in Q1 2017. 45 funds tracked by Wall St. Rank hold VIRX as of Q2 2019.

Vivo Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Vivo Capital sold 2,841 Viracta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $121K.
Vivo Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 10 quarters.
Vivo Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $2.05M in Q1 2017.
45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Vivo Capital's 13F filing for Q2 2019, filed 13 Aug 2019.